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Abstract. High-risk neuroblastoma is the most aggressive form 
of cancer in children. The estimated survival of children with 
high-risk neuroblastoma is 40-50% compared with low and 
intermediate risk neuroblastoma, which is >98 and 90-95%, 
respectively. In addition, patients with high-risk neuroblas-
toma often experience relapse following intensive treatments 
with standard chemotherapeutic drugs. Therefore alternative 
strategies are required to address this problem. MicroRNAs 
(miRNAs/miRs) are small, endogenously expressed 
non-coding RNAs, which when deregulated have been 
demonstrated to serve significant roles in the tumorigenesis of 
a number of different types of cancer. Results from a previous 
deep sequencing study identified 22 downregulated miRNAs 
from the 14q32 miRNA cluster differentially expressed in 
neuroblastoma cell lines isolated from 6 patients at diagnosis 
and at relapse following intensive treatments. miR-376c-3p is 
one of the 22 miRNAs that was downregulated in the majority 
of the cell lines isolated from patients post treatment. The 
present study employed reverse transcription-quantitative 
polymerase chain reaction (RT-qPCR) to quantify the basic 
expression of miR-376c-3p in 6 neuroblastoma cell lines. The 
functional role of miR-376c-3p in the neuroblastoma cell lines 
was evaluated by alamar blue-cell viability and propidium 
iodide‑flow cytometric assays. In addition, luciferase reporter 
assays, RT-qPCR and western blotting were performed to 
identify and quantify the targets of miR-376c-3p in neuro-
blastoma cell lines. Ectopic expression of miR-376c-3p led to 
significant inhibition of cell viability and G1‑cell cycle arrest 
in multiple neuroblastoma cell lines by reducing the expres-
sion of cyclin D1, an oncogene critical for neuroblastoma 
pathogenesis. The results of the present study provide novel 
insights into the functional role of miR-376c-3p and suggest 
new approaches for the treatment of neuroblastoma.
Introduction
Neuroblastoma is the most common childhood malignancy 
derived from the primitive cells of the sympathetic nervous 
system (1). It accounts for ~15% of all pediatric oncology 
deaths (2). The treatment of patients with advanced neuro-
blastoma or high-risk neuroblastoma is still a challenge due 
to several factors including, dose-limiting toxicity to standard 
chemotherapeutic agents, disease heterogeneity and tumor 
regression (3). Moreover, these patients have a very poor 
prognosis with the overall ten-year survival rates of less than 
10% (4). Therefore, the development of innovate alternate 
treatment strategies is necessary to increase the treatment 
effectiveness and lower toxicity.
MicroRNAs (miRNAs/miRs) are a large family of small 
(~22-25 nucleotides), endogenous, non-coding RNAs, which 
binds the partial or perfect complementary sequences in the 
3'untranslated region (3'UTR) of target messenger RNAs 
(mRNAs) leading to translational repression or mRNA degra-
dation (5). They regulate the expression of genes involved in 
proliferation, apoptosis, development and stress response. Thus, 
miRNAs have shown to play an important role in the initiation 
and progression of cancer (5). Depending on their respective 
target, miRNAs can act as oncogenes and or tumor suppres-
sors (6). miRNAs are differentially expressed across cancer 
types and microRNA‑profiling studies have revealed a general 
downregulation in tumors as compared with normal tissues (7). 
Interestingly, growing evidence have now shown the potential 
of aberrant expression of miRNAs to use as the prognostic and 
diagnostic biomarkers of human malignancies (6).
miR-376 family of miRNAs comprises of miR‑376a2, 
miR‑376b, miR‑376c (earlier known as miR‑368), miR‑376b1 
and miR‑376b2 and their sequence identity is highly similar 
to mouse miR‑376a‑c miRNAs (8). miR-376 family members 
are located on chromosome 14 in humans and at the distal 
end of mouse chromosome 12 (9). They are expressed in 
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placenta, developing embryos, and adult tissues (8). The 
expression of miR‑376c is downregulated in many human 
malignancies including cervical cancer (10), prostate 
cancer (11), oral squamous cell carcinoma (12), intrahepatic 
cholangiocarcinoma (13), melanoma (14), osteosarcoma (15) 
and gliomas (16). However, it has been shown that miR‑376c 
is upregulated and it act as oncogenic in acute myeloid 
leukemia (17) and gastric cancer (18). In addition, forced 
expression of miR‑376c enhance ovarian cancer cell survival 
by targeting activing-receptor like kinase 7 (19). Whereas, 
forced overexpression of miR‑376c suppressed growth and 
invasion of non-small cell lung cancer (20). According to our 
knowledge, there is no report regarding the role of miR‑376c in 
neuroblastoma. Thus uncovering the mechanisms of miR‑376c 
function is critical to both the fundamental understanding of 
neuroblastoma pathogenesis and novel therapeutic treatments.
The Cyclin D1 (CCND1) is one of the extensively docu-
mented oncogene in human cancers. Functionally, CCND1 
binds with cyclin-dependent kinases (CDK 4/6) which phos-
phorylate pRB family proteins, which in turn transactivates 
genes necessary for cell cycle progression (21). Dysregulated 
expression of CCND1 is a common feature in various human 
cancers (22,23). Inhibitors targeting CCND1 are thoroughly 
studied but no results have yet been proven effective (22,23). 
The CCND1 gene has one of the longest 3'UTR (~3.1 kb), 
suggesting a strong functional relevance (24). To date, many 
experimentally validated miRNAs targeting CCND1 in 
different cancers are identified. For example, let‑7e, miR‑9‑5p, 
miR‑15a‑5p, miR‑16, miR‑17, miR‑20a, miR‑106b, miR‑34a 
and miR‑206 (25-31). However, no miRNA directly targeting 
CCND1 3'UTR is yet identified in neuroblastoma.
In this study, we examined the relationship between 
miR‑376c‑3p expression and neuroblastoma tumorigenesis. 
In our previous deep sequencing study, we have analyzed 
miR‑376c‑3p expression in neuroblastoma cell lines with 
different genetic characteristics (32). miR‑376c‑3p was down-
regulated in most of the cell lines tested and therefore we 
overexpressed miR‑376c‑3p, which have had significant effects 
on cell growth and survival of neuroblastoma cells.
In addition, we demonstrated that CCND1 is a direct 
target of miR‑376c‑3p in neuroblastoma and overexpression of 
miR‑376c‑3p might have a significant influence on inhibition 
of neuroblastoma tumorigenesis.
Materials and methods
Cell culture. Human neuroblastoma cell lines, CHLA-15 and 
CHLA‑20 were cultivated in Iscove's Modified Dulbecco's 
Medium (Sigma-Aldrich; Merck KGaA, Darmstadt, 
Germany) supplemented with 20% fetal bovine serum, 4 mM 
L-Glutamine and 1X ITS (5 µg/ml insulin, 5 µg/ml trans-
ferrin, and 5 ng/ml selenous acid). CHLA-15 and CHLA-20 
were obtained from the same neuroblastoma patient prior 
to and following treatment with combination chemotherapy 
regimens, respectively. SKNAS, BE(2)-C, Kelly and SHSY-5Y 
cells were grown in RPMI-1640 medium (Sigma-Aldrich; 
Merck KGaA) supplemented with 10% fetal bovine serum 
and 2 mM L‑Glutamine (final concentrations). All cells were 
split before confluence and maintained at 37˚C in a humidified 
incubator with 4.5 to 5% CO2 atmosphere. The cell lines were 
authenticated by short tandem repeat profiling at the Center 
of Forensic Genetics, The Arctic University of Norway-UiT, 
Norway and tested negative for mycoplasma contamination. 
CHLA-15 and CHLA-20 cell lines were kindly provided by 
Children's Oncology Group, Cell Culture and Xenograft 
Repository, Texas Tech University Health Science Centre 
(Lubbock, TX, USA). BE(2)-C, SKNAS, Kelly and SHSY-5Y 
were provided by Dr. John Inge Johnsen (Childhood Cancer 
Research Unit, Department of Women's and Children's Health, 
Karolinska Institutet, Stockholm, Sweden).
Transfections. MicroRNA miR‑376c‑3p mimics or negative 
control (NC) mimics were purchased from GenePharma 
Co., Ltd. (Shanghai, China) and Ambion (Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). Transfections of 
miRNA and NC mimics (25-40 nM) were carried out using 
Lipofectamine® 2000 reagent (Thermo Fisher Scientific, Inc.) 
according to manufacturer's instructions.
Cell viability assay. CHLA-15, CHLA-20, BE(2)-C, Kelly 
and SHSY-5Y cells were seeded in 24-well plates and reverse 
transfected with 25 nM miR‑376c‑3p or NC mimics using 
Lipofectamine® 2000 reagent (Thermo Fisher Scientific, Inc.). 
Every 24 h post-transfection, alamarBlue® (Thermo Fisher 
Scientific, Inc.) cell viability assay was performed according 
to manufacturer's instructions. Ten percent of the alamarBlue 
reagent was added to the cultured cells, mixed gently and 
incubated at 37˚C for three hours. 100 µl of medium was then 
transferred to black-walled 96-well plate and fluorescence 
was monitored at 540 nm excitation wavelength and 590 nm 
emission wavelength in a microplate reader (CLARIOstar; 
BMG Labtech GmbH, Offenburg, Germany). Cell viability 
was calculated as the percentage of NC transfected cells set 
to 100 percent.
Flow cytometric analysis of cell cycle distribution. The 
BE(2)-C, Kelly and SHSY-5Y cells were seeded in 25 cm2 
culture flasks and reverse transfected with 25 nM mimics as 
described previously. 24 h post-transfection cells were tryp-
sinized and washed with 1X phosphate-buffered saline (PBS). 
The cells were then fixed in ice‑cold 70% ethanol and incu-
bated overnight at -20˚C. Next day, the ethanol fixed cells were 
centrifuged for 10 min at 0.8 x g and washed twice with 1X 
PBS and resuspended in the propidium iodide (PI) (Thermo 
Fisher Scientific, Inc.) staining solution (PBS with 100 µg/ml 
RNase, 50 µg/ml PI). The cells were then incubated for 30 min 
protected from light and stored on ice until analyzed. 
Fluorescence emitted from the PI-DNA complex was analyzed 
by flow cytometry using BD LSRFortessa™ cell analyzer (BD 
Biosciences, Franklin Lakes, NJ, USA). FlowJo 7.6.5 software 
was used to analyze the cell cycle data using the Dean-Jett-Fox 
model for cell cycle evaluation.
Bioinformatics target prediction. TargetScan (version 6.2; 
www.targetscan.org/) target prediction software was used to 
predict miR-376c-3p targets related to cell cycle.
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR). The Kelly, SHSY-5Y and BE(2)-C cells were seeded 
in 6-well plates and transfected with 40 nM of miR‑376c‑3p or 
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NC mimics. Cells were harvested 48 h post-transfection and 
total RNA was isolated with QIAzol®Lysis reagent (Qiagen 
Sciences, Inc., Gaithersburg, MD, USA) according to manu-
facturer's instructions and quantified by NanoDrop™ 1000 
spectrophotometer (Thermo Fisher Scientific, Inc.).
For miRNA expression analysis, complementary DNA 
(cDNA) was synthesized from isolated total RNAs using 
the miScript II RT kit (Qiagen Sciences, Inc.) according to 
manufacturer's instructions. The reaction mixture (1X) (20 µl 
reaction volume) for reverse transcription was as follows: 
Total RNA, 1 µg (diluted in RNase Free Water up to 12 µl); 
5X miScript HiSpec Buffer, 4 µl; 10X miScript Nucleics Mix, 
2 µl; miScript Reverse Transcriptase Mix, 2 µl; The cycling 
conditions were 37˚C for 60 min followed by 95˚C for 5 min. 
The cDNA obtained was diluted with 80 µl RNase Free 
Water to achieve 10 ng/µl concentration and stored at ‑20˚C 
until use. To quantitate miR‑376c‑3p levels, quantitative poly-
merase chain reaction was performed with miScript primer 
assay for miR-376c (cat. no MS00004046) using miScript 
SYBR®Green PCR kit (Qiagen Sciences, Inc.,). The miScript 
primer assay for miR-4286 (cat. no MS00021371) was used 
as an internal control for normalization. The reaction mixture 
(1X) (20 µl reaction volume) for real time PCR was as follows: 
cDNA (1 ng/5 µl), 5 µl; QuantiTect SYBR-Green PCR Master 
Mix, 10 µl; Specific miScript primer assay, 2 µl; 10X miScript 
Universal Primer, 2 µl; RNase Free Water, 1 µl.
For basic miRNA expression levels in neuroblastoma 
cell lines, the following method was used for calculations. 
Raw fluorescence values (non‑baseline corrected) gener-
ated from RT-qPCR reactions were used to calculate mean 
PCR efficiencies in the LinRegPCR software (Version 11.0; 
http://LinRegPCR.HFRC.nl.). N0 values (starting concen-
trations calculated by LinRegPCR software, N0=threshold/ 
(mean amplicon efficiencyCq)) were used to calculate the 
expression of miR‑376c‑3p relative to the stably expressed 
miR‑4286 (32). qPCR reactions were performed in trip-
licates on 2 independent biological replicates. Standard 
deviations were calculated taking into account the principle 
of error propagation (including technical and biological 
replicates).
For mRNA expression analysis, complementary DNA 
(cDNA) was synthesized from isolated total RNAs using 
the maxima reverse transcriptase (Thermo Fisher Scientific, 
Inc.) according to manufacturer's instructions. The reaction 
mixture (1X) (20 µl reaction volume) for reverse transcription 
of mRNAs was as follows: Oligo DT primer (20 µM), 1 µl; 
dNTP (10 mM each), 1 µl; Total RNA, 1 µg (diluted in RNase 
Free Water up to 13.75 µl); Incubate 65˚C for 5 min followed by 
addition of 5x RT Buffer, 4 µl; Maxima Reverse Transcriptase, 
0.25 µl; The cycling conditions were 60˚C for 30 min followed 
by 85˚C for 5 min. The cDNA obtained was diluted with 80 µl 
RNase Free Water to achieve 10 ng/µl concentration and 
stored at ‑20˚C until use. To quantitate CCND1 levels, quan-
titative polymerase chain reaction was performed with Power 
SYBR-Green PCR Master Mix (Thermo Fisher Scientific, 
Inc.). SDHA housekeeping gene was used as an internal control 
for normalization. The reaction mixture (1X) (20 µl reaction 
volume) for real time PCR was as follows: cDNA (1 ng/1 µl), 
10 µl; Power SYBR-Green PCR Master Mix, 5 µl; Forward 
Primer (10 µM), 0.4 µl; Reverse Primer (10 µM), 0.4 µl; RNase 
Free Water 4.2 µl.
Amplifications were carried out using Light Cycler 96 
SW 1.1 (Roche Diagnostics GmbH, Mannheim, Germany) and 
expression levels of miRNAs and mRNAs were evaluated using 
the comparative ΔΔCq comparative cycle threshold method (33). 
The primers used were CCND1 (forward: 5'-CCG TCC ATG 
CGG AAG ATC-3'; reverse: 5'-ATG GCC AGC GGG AAG AC-3') 
and SDHA (forward: 5'-CTG ATG AGA CAA GAT GTG GTG-3'; 
reverse: 5'-CAA TCT CCC TTC AAT GTA CTC C-3').
Western blot analysis. Cells were trypsinized and lysed in 
40 µl RIPA buffer (50 mM Tris-HCL pH 8, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented 
with 1X Protein Inhibitor Cocktail (Roche Diagnostics 
GmbH) and 1 mM dithiothreitol (DTT). Lysate was cleared 
with centrifugation (21.1 x g) and the total protein concentra-
tions were determined using DCTMProtein Assay kit (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) according to manu-
facturer's instructions. 40 µg protein was then loaded in each 
well and separated on a NuPAGE® Novex 4-12% Bis-Tris 
precast polyacrylamide gel (Thermo Fisher Scientific, Inc.). 
The separated proteins were transferred on Immobilon-FL 
PVDF membrane (EMD Millipore, Billerica, MA, USA) and 
blocked for 1 h at room temperature in 5 ml Odyssey Blocking 
Buffer (LI-COR Biosciences, Lincoln, NE, USA). The PVDF 
membrane was then incubated overnight at 4˚C with primary 
antibodies anti-Cyclin D1-(H-295)-Human Cyclin D1 Rabbit, 
polyclonal; (1:1,000; Santa Cruz Biotechnology, Inc., Dallas, 
TX, USA) and anti-actin-(ab3280)-Human Actin Mouse, 
monoclonal (1:1,000; Abcam, Cambridge, UK). The secondary 
antibodies used were goat anti-rabbit-IRDye800CW, (1:5,000) 
(Rockland Immunochemicals, Inc., Gilbertsville, PA, USA) 
and goat anti-mouse-Alexa Fluor 680, (1:5,000; Thermo 
Fisher Scientific, Inc.). Antibody binding was detected 
using the Odyssey CLx Infrared Imaging System (LI-COR 
Biosciences). ImageJ software was used to quantify western 
blot results.
Luciferase reporter assay. The pMIR-Report-Cyclin 
D1-UTR-WT construct was a generous gif t f rom 
Dr. Laura Barkley (30) and pMIR-Report-Cyclin D1-UTR-MUT 
construct with a mutation in the putative miR‑376c‑3p seed 
sequence (mutant) was generated using QuikChange® Multi 
Site-Directed Mutagenesis kit (Agilent Technologies, Inc., 
Santa Clara, CA, USA). The primers used for mutagenesis 
were CCND1_3'UTR_miR-376c-3p (forward: 5'-CAC ATC 
TTG GCA TAC TAA TTC TTG-3'; reverse: 5'-CAA GAA TTA 
GTA TGC CAA GAT GTG-3'). To validate for mutation in seed 
sequence the mutant plasmid was sequenced using sequencing 
primer 5'-CAT CTG ATT GGA CAG GCA TG-3'. The cells 
seeded at a density of 5x104cells/well in a 12-well plate were 
co-transfected with 40 nM NC or miR‑376c‑3p mimics, 20 ng 
pRL-SV40 construct (Promega Corporation, Madison, WI, 
USA) and 100 ng wild type or mutant luciferase constructs using 
Lipofectamine® 2000 reagent (Thermo Fisher Scientific, Inc.). 
24 h post‑transfection, firefly and renilla luciferase activities 
analyzed using the Dual-Luciferase Reporter Assay (Promega 
Corporation), according to manufacturer's instructions. Firefly 
luciferase activity was normalized against renilla luciferase 
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activity and luciferase activities of miR‑376c‑3p transfected cells 
were calculated relative to NC transfected cells set to 100 %.
MicroRNA expression data from neuroblastoma tumors. 
miRNA expression data from 226 primary neuroblastoma 
tumors were obtained through the Neuroblastoma Research 
Consortium (NRC). Differential miRNA expression was 
analyzed using a Kruskal-Wallis test.
Statistical analysis. The data was expressed as mean ± standard 
deviation (SD). Unless otherwise stated, all experiments were 
performed at least three times independently. Statistical 
analysis was performed using the software GraphPad Prism 
version 5.00 for Windows (GraphPad Software, Inc., La Jolla, 
CA, USA; available at www.graphpad.com). Statistical differ-
ences between means were determined using Student's t-test. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Multiple miRNAs located at 14q32 chromosomal region are 
downregulated and their lower levels are associated with 
poor prognosis factors in neuroblastoma. Results from our 
previous study, where we used next generation sequencing 
technology (SOLiD ligation sequencing) to determine miRNA 
expression profiles in neuroblastoma cell lines established 
from patients at diagnosis and at relapse after treatment, 
identified 22 downregulated microRNAs from 14q32 miRNA 
cluster. The expression of these downregulated miRNAs was 
confirmed in a cohort consisting of 226 primary neuroblas-
tomas (32). miR‑376c‑3p, was one of the 22 miRNAs that was 
downregulated in most of the cell lines isolated from patients 
after the treatment (Fig. 1A). When miR‑376c expression 
was compared in neuroblastoma primary tumors of different 
stages from the 226-cohort, we observed a trend towards lower 
expression in advanced stage disease compared to tumors in 
stage 1 (Fig. 1B). Thus, we sought out to focus on the func-
tional role of miR‑376c‑3p in neuroblastoma.
miR‑376c‑3p reduces cell viability in neuroblastoma cell 
lines. Even though miR‑376c‑3p has been shown to play 
either the oncogenic or the tumor suppressive role in different 
cancers (10-20) the functional role of miR‑376c‑3p is not 
yet determined in neuroblastoma. Therefore, we first used 
RT-qPCR to measure miR‑376c‑3p basic expression levels 
relative to miR‑4286 in 6 neuroblastoma cell lines. miR‑4286 
was previously showed to be stably expressed in neuroblastoma 
cell lines (32). Among the cell lines, SKNAS and BE(2)-C cells 
have the highest expression level of miR‑376c‑3p, whereas 
SHSY-5Y, Kelly, CHLA-15 and CHLA-20 cells showed barely 
detectable levels of expression (Fig. 2A). In order to find out the 
potential role of miR‑376c‑3p in neuroblastoma, cell viability 
assay was performed on several neuroblastoma cell lines by 
overexpressing NC or miR‑376c‑3p mimics. The expression 
of miR‑376c‑3p was significantly increased in miR‑376c‑3p 
transfected cell lines compared with NC transfected cells, as 
validated and confirmed by RT‑qPCR (Fig. 2B). Cell viability 
alamarBlue assay was performed at 24, 48, 72 and 96 h 
post-transfection, which showed that neuroblastoma cell 
lines transfected with miR‑376c‑3p mimics, had significantly 
reduced cell viability as compared to NC transfected cells. 
Thus, ectopic expression of miR‑376c‑3p reduced the growth of 
SKNAS, CHLA-15, CHLA-20, SHSY-5Y, Kelly and BE(2)-C 
cells as compared to NC transfected cells (Fig. 2C). These 
results indicate that cell growth of neuroblastoma cell lines is 
significantly affected by overexpression of miR‑376c‑3p.
miR‑376c‑3p induces a G1‑cell cycle arrest in neuroblastoma 
cells. We did not detect significant apoptosis in miR‑376c‑3p 
transfected neuroblastoma cells using Annexin V and PARP 
cleavage assay (data not shown). Thus, we investigated the 
effects of miR‑376c‑3p overexpression on cell cycle distribu-
tion of representative neuroblastoma cell lines BE(2)-C, Kelly 
and SHSY‑5Y by flow cytometric assay. Ectopic expression 
of miR‑376c‑3p in BE(2)-C, Kelly and SHSY-5Y resulted 
in increased percentage of cells in G1-phase of cell cycle 
as compared to NC transfected cells by 13% (**P=0.0023), 
Figure 1. (A) Schematic representation of the miRNA-cluster at 14q32 chro-
mosomal region. Multiple miRNAs located at 14q32 chromosomal region 
are downregulated (bold type) and associated with poor prognosis factors 
in neuroblastoma. The miRNA of interest, miR-376c-3p is shown in bold 
and a rectangular box. (B) Box-plots of miR-376c expression in tumors from 
neuroblastoma patients at different stages. The boxes represent the 25-75% 
quartiles. The horizontal line in the boxes represents the median level. 
Whiskers represent the non-outlier range. Open circles represent the outliers. 
P=0.011, comparing the median expression level of miR376c-3p across all 
pathological stages. DLK1, Delta Like Non-canonical Notch Ligand 1; MEG, 
maternally expressed; snoRNA, small nucleolar RNAs; DIO3, iodothyronine 
deiodinase 3; miR/miRNA, microRNA.
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16% (***P=0.0001) and 9% (*P=0.0106), respectively with 
a corresponding reduction in the percentage of cells in the 
S and G2/M-phase (Fig. 3). Thus, this observation led us to 
the conclusion that decrease in cell viability might be due to 
induction of G1-cell cycle arrest in neuroblastoma cells and 
not apoptosis.
CCND1 is a direct target of miR‑376c‑3p in neuroblastoma. 
In order to investigate the underlying molecular mechanisms 
of miR‑376c‑3p induced suppression of the cell viability and 
G1-cell cycle arrest, a bioinformatics analysis was performed 
using miRNA target prediction algorithm TargetScan 
(Release 6.2; www.targetscan.org/) to predict the target genes 
of miR‑376c‑3p mainly associated with the cell cycle progres-
sion. TargetScan revealed 254 potential downstream targets 
with the conserved sites for miR‑376c‑3p (data not shown). 
It was theoretically demonstrated that miR‑376c‑3p had 
single binding site in the 3'UTR of CCND1 oncogene. Thus, 
to determine whether miR‑376c‑3p could directly target the 
predicted 3'UTR of CCND1, a dual-luciferase reporter assay 
was performed in BE(2)-C and SHSY-5Y cells. Here, we used 
a luciferase reporter containing full-length (~3.1 kb), wild 
type CCND1 3'UTR (wt) or mutant CCND1 3'UTR (MUT) 
construct having a mutation of the putative miR‑376c‑3p target 
site shown in bold and italics (Fig. 4A).
Transient co-transfection of BE(2)-C and SHSY-5Y cells 
with miR‑376c‑3p mimics and the wild type CCND1 3'UTR 
(wt) reporter construct suppressed the luciferase activity 
as compared to NC transfected cells by 35% (**P=0.0091) 
and 38% (*P=0.0135), respectively. However, the activity of 
the reporter construct mutated at the specific miR‑376c‑3p 
target site is unaffected (Fig. 4B). These data indicated that 
miR‑376c‑3p represses CCND1 expression by directly binding 
to the 3'UTR sequence of CCND1 mRNA.
miR‑376c‑3p reduces mRNA and protein levels of CCND1 in 
neuroblastoma cells. To further confirm whether miR‑376c‑3p 
directly targets CCND1 gene, neuroblastoma cells were 
transfected with miR‑376c‑3p or NC mimics and the expres-
sion levels of CCND1 was analyzed by quantitative RT-qPCR 
analysis. The levels of CCND1 mRNA was markedly 
decreased by miR‑376c‑3p overexpression in BE2-(C), Kelly 
and SHSY-5Y cells by 57% (*P=0.0110), 57% (**P=0.0017), 
and 53% (*P=0.0134), respectively as compared to NC trans-
fected cells (Fig. 5A). Moreover, we also performed western 
blot analysis and observed significant decrease in levels 
of cyclin D1 proteins upon miR‑376c‑3p overexpression in 
BE2-(C), Kelly and SHSY-5Y cells by 41% (**P=0.0089), 67% 
(**P=0.0032), and 69% (**P=0.0069), respectively as compared 
to NC transfected cells (Fig. 5B and C). Taken together, these 
results demonstrates that endogenous expression of CCND1 
gene is directly regulated by miR‑376c‑3p and suggest that 
overexpression of CCND1 gene could be reduced by enforced 
expression of miR‑376c‑3p in neuroblastoma cells.
In addition, to test whether CCND1 could also counteract 
the effect of miR‑376c‑3p induced G1 cell cycle arrest, we 
overexpressed CCND1 in SHSY-5Y cells. However, we only 
saw a modest and statistically insignificant effect of CCND1 
overexpression on reducing the effect of miR-376c-3p (Fig. 6).
Discussion
Current treatment strategies for high-risk neuroblastoma 
patients have limitations due to the refractory nature of the 
disease (2-4). Hence, alternative strategies are necessary for 
diagnosis and treatment of this disease. Mounting evidence 
have shown the potential of miRNAs as key regulators of 
Figure 2. miR-376c-3p reduces cell viability in neuroblastoma cell lines. 
(A) RT-qPCR analysis was performed to quantitate the basic expression of 
miR‑376c‑3p in 6-neuroblastoma cell lines. miR‑4286 served as an endog-
enous control for miRNAs. Error bars indicate mean ± SD of two independent 
experiments, each repeated in triplicate. (B) RT‑qPCR analysis for confirma-
tion of miR‑376c‑3p overexpression in 6-neuroblastoma cell lines transfected 
with NC or miR‑376c‑3p mimics. Expression of miR‑376c‑3p in SHSY-5Y cell 
line was set to 1 and miR‑4286 served as an endogenous control for miRNAs. 
Error bars indicate mean ± SD. of two independent experiments, each repeated 
in triplicates. (C) Cell growth analysis of neuroblastoma cells transfected 
with NC or miR‑376c‑3p mimics. BE(2)-C, Kelly and SHSY-5Y were more 
sensitive compared with SKNAS, CHLA-15 and CHLA-20. Error bars indi-
cate mean ± SD of three independent experiments repeated in triplicate. The 
results were statistically significant at 48, 72 and 96 h for all cell lines. *P<0.05. 
RT-qPCR, reverse transcription-quantitative polymerase chain reaction; NC, 
negative control; SD, standard deviation; miR, microRNA.
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cancer pathogenesis by acting as oncogenes or tumor suppres-
sors (6). Researchers have thus exploited these properties for 
the development of the novel anticancer therapies. miRNAs 
act by inhibiting the expression of its one or more target genes. 
Hence, identification of specific miRNAs and their targets is 
very important for the diagnosis and therapy of cancer (34).
Results from our previous deep sequencing analysis study 
identified 22 downregulated microRNAs from 14q32 miRNA 
cluster differentially expressed in neuroblastoma cell lines 
isolated from six patients at diagnosis and at relapse after 
intensive treatments. miR‑376c‑3p, is one of the 22 miRNAs 
that was downregulated in most of the cell lines isolated 
from patients after treatment (32). Moreover, the expression 
of miR‑376c‑3p was reduced in International Neuroblastoma 
Staging System (INSS) stage 4 compared to stage 1-2 in a 
cohort of 226 primary neuroblastoma tumors (32). However, 
Figure 3. miR‑376c‑3p induces G1-cell cycle arrest in neuroblastoma cells. BE(2)-C, Kelly and SHSY-5Y cells were transfected with NC or miR‑376c‑3p 
mimics and the cell cycle analysis was evaluated by a propidium iodide‑flow cytometric assay. The percentage of G1‑arrested cells increased after miR‑376c‑3p 
overexpression. Error bars indicate mean ± standard deviation of three independent experiments repeated in triplicates. NC, negative control; miR, microRNA 
*P<0.05, **P<0.01 and ***P<0.001 vs. NC.
Figure 4. CCND1 is a direct target of miR‑376c‑3p in neuroblastoma. (A) The CCND1 3'UTR contain one predicted miR‑376c‑3p binding site (nucleotides 
1,792 to 1,798). In the figure, the alignment of the seed region of miR‑376c‑3p with CCND1 and the site of target mutagenesis are shown in bold and italics. 
(B) pMIR-Report-CCND1 luciferase constructs containing a full-length wt or mutated CCND1 3'UTR and miR‑376c‑3p or NC mimics, were co-transfected 
into BE(2)‑C and SHSY‑5Y cells. Luciferase activity of wt construct was significantly reduced compared with mutated constructs. Relative repression of firefly 
luciferase activity is normalized with renilla luciferase activity. Error bars indicate mean ± standard devaition of three independent experiments repeated in 
triplicates. *P<0.05, **P<0.01 vs. the adjacent NC. miR, microRNA; NC, negative control; CCND1, cyclin D1; ORF, open reading frame; UTR, untranslated 
region; wt, wild type; MUT, mutated.
ONCOLOGY LETTERS  16:  6786-6794,  20186792
the functional role of miR‑376c‑3p in neuroblastoma is not yet 
established.
Earlier reports from various cancers have demonstrated 
the dual nature of miR‑376c‑3p to act as either the oncogenic 
or the tumor suppressive miRNA depending on the cellular 
contexts (10-20). miR‑376c‑3p is downregulated in multiple 
human cancers, including prostate cancer (11), cervical 
cancer (10), oral squamous cell carcinoma (12), intrahepatic 
cholangiocarcinoma (13), melanoma (14), osteosarcoma (15) 
and gliomas (16). In contrast, miR‑376c‑3p was upregulated 
in acute myeloid leukemia (17) and gastric cancer (18). In 
these cancers, miR‑376‑3p has been shown to target a set of 
genes including B-cell-specific moloney murine leukemia 
virus insertion site 1 (BMI1), homeobox B7 (HOXB7), 
growth factor receptor-bound protein 2 (GRB2), transforming 
growth factor-alpha (TGFA), liver receptor homolog-1 
(LRH-1), insulin growth factor 1 receptor (IGF1R) and activin 
receptor-like kinase 7 (ALK7). Other than affecting cell 
growth and proliferation, these genes act as important media-
tors of cell invasion (10,12,15, 20), migration (11-14), cell cycle 
arrest (10), apoptosis (12) and chemoresistance (19).
In order to find out how miR‑376c‑3p affects the growth 
and viability of neuroblastoma cells we first performed 
alamarBlue cell viability assay and demonstrated that tran-
sient overexpression of miR‑376c‑3p resulted in inhibition 
of cell viability in neuroblastoma cell lines. Consistent with 
this finding, we also observed that miR‑376c‑3p induced 
G1-cell cycle arrest suggesting that cell cycle genes may be 
affected and could serve as miR‑376c‑3p targets. To test this 
hypothesis, we used miRNA bioinformatics algorithms to 
predict miR‑376c‑3p targets related to the cell cycle regulation. 
TargetScan algorithm predicted the CCND1 gene as a prob-
able target of miR‑376c‑3p. CCND1 is an important cell cycle 
regulator whose mRNA contains a conserved miR‑376c‑3p 
binding site on the 3'UTR. By dual-luciferase reporter assay, 
we further demonstrated that miR‑376c‑3p could signifi-
cantly reduce luciferase activity of wild type constructs but 
not mutated CCND1 3'UTR construct confirming the direct 
regulation on CCND1 by miR‑376c‑3p. Our experimental data 
further showed that the expression of CCND1 mRNA and 
protein levels were significantly reduced after transfection with 
miR‑376c‑3p mimics as compared to NC mimics transfected 
cells. Additionally, we also performed flow cytometric rescue 
experiment by overexpression of CCND1 in neuroblastoma 
cells to see if CCND1 counteracts the effect of miR‑376c‑3p 
induced G1 cell cycle arrest. However, we only saw a modest 
and statistically insignificant effect of CCND1 overexpression 
on reducing the effect of miR‑376c‑3p overexpression.
Cyclin D1, Cyclin D2 and Cyclin D3 belongs to the class of 
cyclins, which activates the cyclin-dependent kinases (CDKs). 
These cyclins through the phosphorylation of the substrates 
at specific cell stages co-ordinates the sequential comple-
tion of DNA replication and cell division (23). Unlike other 
cyclins, CCND1 is induced by extracellular signals, including 
Figure 5. miR‑376c‑3p reduces mRNA and protein levels of CCND1 in 
neuroblastoma cells. (A) miR‑376c‑3p overexpression significantly decreases 
CCND1 mRNA levels in BE(2)-C, Kelly and SHSY-5Y. These cells were 
transfected with NC or miR‑376c‑3p mimics for 48 h and CCND1 levels 
were assessed by reverse transcription-quantitative polymerase chain reac-
tion. (B) miR‑376c‑3p overexpression significantly decreases endogenous 
levels of Cyclin D1 proteins in BE(2)-C, Kelly and SHSY-5Y. These cells 
were transfected with NC or miR‑376c‑3p mimics for 96 h and Cyclin D1 
expression assessed by western blot analysis. The β-actin antibody used as 
a loading control. (C) Quantitative analysis of Cyclin D1 protein expression 
on the western blots (n=3). Error bars indicate mean ± standard deviation of 
three independent experiments. *P<0.05 and **P<0.01 vs. the adjacent NC. 
miR, microRNA; NC, negative control; CCND1, cyclin D1.
Figure 6. CCND1 overexpression partially rescues neuroblastoma cells from 
miR‑376c‑3p induced G1 cell cycle arrest. SHSY-5Y cells were co-transfected 
with NC or miR‑376c‑3p mimics and an empty or cyclin D1 overexpression 
plasmid. 96 h after the transfection, cells were ethanol fixed and cell cycle 
analysis was evaluated by the PI‑flow cytometric assay. The results of the cell 
cycle analysis are depicted as percentage of cells in particular phases of cell 
cycle. Error bars indicate mean ± standard deviation of at least three repeats. 
miR, microRNA; NC, negative control; CCND1, cyclin D1.
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growth factor receptor activation and integrin-derived 
adhesion signaling (23,35). Functionally, CCND1 activates 
CDK4/6, which phosphorylates pRB family proteins causing 
the release of E2F transcription factors, which are essential 
for transcription of genes necessary for G1-S transition of cell 
cycle. Hence, the expression of cyclins are tightly regulated by 
variety of signaling pathways at the transcriptional as well as 
post-transcriptional levels (21).
The CCND1 gene has been proposed as an important onco-
gene in various cancers. Numerous studies have documented 
the relationship between deregulation of CCND1 and onset 
of tumorigenesis in wide variety of cancers. For instance, 
Molenaar et al (36,37) found that CCND1 levels were increased 
in neuroblastoma tumors and high expression of CCND1 led to 
tumorigenesis in neuroblastoma. In addition, Rihani et al (22) 
found that knockdown of CCND1 reduced cell proliferation, 
induced G1-cell cycle arrest and inhibited the cyclin D1-Rb 
pathway in neuroblastoma cells. Similarly, Sun and colleagues 
also found that inhibition of CCND1 and CDK6 by miR‑34a 
resulted in G1-cell cycle arrest in non-small cell lung 
cancer (38). In line with these reports, our data indicate that 
ectopic expression of miR‑376c‑3p leads to the suppression of 
endogenous CCND1 gene resulting in the reduced cell growth 
and G1-cell cycle arrest in the neuroblastoma cells.
Taken together, our study for the first time demonstrates 
that miR‑376c‑3p directly target CCND1 gene leading to 
reduced cell growth and G1-cell cycle arrest in neuroblastoma. 
Therefore, we suggest that ‘miR‑376c‑CCND1’ axis could 
be a potential molecular target for preventing neuroblastoma 
tumorigenesis.
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